The notices it replaced
- Reissues: PAR-20-116 Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)
Replaced by PAR-25-336.
Who won it before
22 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $14,238,409 in first-year total cost, median $608,697.
Most frequent study sections
- Special Emphasis Panel[ZRG1 IMST-U (55)]7
- Special Emphasis Panel[ZRG1 MCST-U (55)]7
- Special Emphasis Panel[ZRG1 IMST-A (55)]4
- Special Emphasis Panel[ZRG1 IMST-M (55)]4
Most frequent institutions
- UNIVERSITY OF TX MD ANDERSON CAN CTR2
- CEDARS-SINAI MEDICAL CENTER1
- EMORY UNIVERSITY1
- FRED HUTCHINSON CANCER RESEARCH CENTER1
- MASSACHUSETTS GENERAL HOSPITAL1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Translational development of osteosarcoma (OS) extracellular vesicle (EV) matrix metalloproteinase (MMP) Activity Assay for assessing patient treatment responses1R01CA298883-01 | JONAS, STEVEN JOHNTSENG, HSIAN-RONGZHU, YAZHEN | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $2,097,875 | ZRG1 |
| 2025 | Interstitial Chemophototherapy as an Intervention in Locally Advanced Pancreatic Cancer1R01CA298877-01 | LIU, TRACY WLOVELL, JONATHAN FSHAFIRSTEIN, GAL | STATE UNIVERSITY OF NEW YORK AT BUFFALO, NY | $677,176 | ZRG1 |
| 2024 | Designer extracellular vesicles for cancer therapy1R01CA284182-01A1 | XU, XIAOWEI | UNIVERSITY OF PENNSYLVANIA, PA | $662,946 | ZRG1 |
| 2024 | Development of novel nanotherapeutics to overcome therapy resistance using canine brain tumor as a spontaneous model1R01CA294557-01 | LI, YUANPEI | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $634,743 | ZRG1 |
| 2023 | Next Gen Targeted nanoparticles for Inhibiting Gli2 in Bone Metastatic Tumors1R01CA264508-01A1 | DUVALL, CRAIG LEWISRHOADES (STERLING), JULIE A | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $667,924 | ZRG1 |
| 2023 | Chip-Scale Intraoperative Optical Navigation with Immunotargeted Upconverting Nanoparticles1R01CA278672-01A1 | ANWAR, MEKHAILCOHEN, BRUCE E | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $655,333 | ZRG1 |
| 2023 | Targeted RNA delivery using ribonucleoprotein1R01CA268985-01A1 | GAO, XIAOHU | UNIVERSITY OF WASHINGTON, WA | $604,082 | ZRG1 |
| 2023 | Targeting tumor microenvironment by nanoimmunodrugs for glioma treatment1R01CA284247-01 | LJUBIMOV, ALEXANDER V | CEDARS-SINAI MEDICAL CENTER, CA | $577,033 | ZRG1 |
| 2023 | Engineering In Vivo Chimeric Antigen Receptor Macrophages (CARMs) using mRNA-exosomes for Cancer Immunotherapy1R01CA284108-01 | JIANG, WENKIM, BETTY | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $567,816 | ZRG1 |
| 2023 | Customized nanofibers with preferential lung-targeting properties for treating metastatic pulmonary tumors1R37CA278671-01 | BELLAT, VANESSA | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $511,558 | ZRG1 |
| 2022 | Toward translation of a plant virus-based in situ vaccination nanotechnology1R01CA274640-01 · under PAR-20-116 | FIERING, STEVENRANJAN, ASHISHSTEINMETZ, NICOLE FRANZISKA | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $649,918 | ZRG1 |
| 2022 | Pre-IND Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy1R01CA257842-01A1 · under PAR-20-116 | CHOW, DIANA S-L.LI, CHUNYANG, PEIYING | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $642,984 | ZRG1 |
| 2022 | Towards Translation of MU-CN29: New Therapeutic Nanoparticle for Drug-Resistant NSCLC1R01CA274677-01 · under PAR-20-116 | KANNAN, RAGHURAMAN | UNIVERSITY OF MISSOURI-COLUMBIA, MO | $622,068 | ZRG1 |
| 2022 | Toward Translation of an Immunotherapeutic Nanomedicine for Neuroblastoma1R01CA274675-01 · under PAR-20-116 | WILSON, JOHN TANNER | VANDERBILT UNIVERSITY, TN | $604,335 | ZRG1 |
| 2021 | High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer1R01CA264363-01 · under PAR-20-116 | CASTRO, CESAR MLEE, HAKHO | MASSACHUSETTS GENERAL HOSPITAL, MA | $662,338 | ZRG1 |
| 2021 | TOWARD TRANSLATION OF NANFORMULATED PACLITAXEL-PLATINUM COMBINATION1R01CA264488-01 · under PAR-20-116 | KABANOV, ALEXANDER V | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $613,059 | ZRG1 |
| 2021 | Systemic delivery of siRNA by Nanosac for checkpoint blockade immunotherapy of head and neck squamous cell cancer1R01CA258737-01 · under PAR-20-116 | KRON, STEPHEN J.YEO, YOON | PURDUE UNIVERSITY, IN | $602,006 | ZRG1 |
| 2021 | Rapid and affordable magneto-nanosensors for ctDNA-guided lung cancer management1R01CA257843-01A1 · under PAR-20-116 | WANG, SHAN X. | STANFORD UNIVERSITY, CA | $573,461 | ZRG1 |
| 2021 | Development of a novel biodegradable inorganic nanoparticle therapeutic for cancer1R01CA257851-01 · under PAR-20-116 | KIM, WILLIAM Y.LI, ZIBOXIE, JIN | UNIVERSITY OF GEORGIA, GA | $552,591 | ZRG1 |
| 2021 | Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis1R01CA257861-01 · under PAR-20-116 | YANG, LILY | EMORY UNIVERSITY, GA | $542,085 | ZRG1 |
| 2021 | Oligo(lactic acid)n-Prodrug Nanomedicines for Combination Therapy1R01CA257837-01 · under PAR-20-116 | KWON, GLEN S. | UNIVERSITY OF WISCONSIN-MADISON, WI | $347,945 | ZRG1 |
| 2021 | Developing macrophage reprogramming mRNA nanocarriers for initial clinical testing1R01CA263524-01 · under PAR-20-116 | STEPHAN, MATTHIAS | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $169,133 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.